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Introduction
The success achieved in the past few years in the 
HIV infection treatment has not been paralleled by 
remarkable improvements in the effectiveness of HIV 
prevention strategies [1, 2]. More than 1.8 million new 
HIV-1 infections were reported in 2017 worldwide, and 
an incidence rate equal to 5.7 new cases per 100,000 
residents emerged in Italy [2].
As result, innovative and potent prevention strategies 
were required to reduce the risk of viral transmission 
from infected persons to healthy individuals, given the 
poor adherence to the traditional prevention strategy, as 
condoms and needle-syringe programs (NSPs). In the 
last few years, the use of oral tenofovir/emtricitabine 
(FTC/TDF), for pre-exposure prophylaxis (PrEP) 
among high-risk persons without HIV, has emerged as 
an innovative strategy to decrease HIV epidemic.
PrEP was approved by the Food and Drug Administration 
in 2012, and the US Centers for Disease Control and 
Prevention (CDC) released clinical guidelines on its use in 
2014, on the basis of the drugs’ clinical effectiveness [3-
6], thus recommending the use of PrEP, in addition to 
condoms and NSPs, for HIV negative individuals, with 
the following characteristics [7]: 1) serodiscordant sexual 
relationship; 2)  anyone who is not in a monogamous 
relationship with an HIV negative person; 3) men who 
have sex with other men; 4)  sexual risk in general, 
Introduction. The use of oral tenofovir/emtricitabine (FTC/
TDF) for pre-exposure prophylaxis (PrEP) among high-risk 
people without Human Immunodeficiency Virus (HIV), is emerg-
ing as an innovative strategy to decrease HIV epidemic. The 
study aims at evaluating the implications related to PrEP intro-
duction, from a multidimensional point of view, as required by 
Health Technology Assessment (HTA) approach, with a particu-
lar attention on sustainability and social factors, influencing 
PrEP implementation.
Methods. An analysis was conducted involving 35 Italian Infec-
tious Disease Departments. The introduction of PrEP (applied 
both as “add-on” and “substitute” prevention strategy) into the 
clinical practice was compared with a baseline scenario, con-
sisting of condoms among men who have sex with men, and sero-
discordant couples, and the use of Needle Syringe Programme 
among injection drugs users The above scenarios were analysed 
by means of a Health Technology Assessment (HTA) approach. 
The 9 EUnetHTA Core Model domains were assessed through 
comparative information, retrieved from literature evidence, and 
collection of qualitative and quantitative information, derived 
from real-world evidence, in particular from 35 Infectious Dis-
ease Departments and potential PrEP’ users involved. A final 
multi-criteria decision analysis approach (MCDA) was imple-
mented to simulate the appraisal phase and providing evidence-
based information with regard to the preferable technology. 
Results. Despite the improvement in patients’ quality of life, PrEP 
would generate the development of other sexually transmitted and 
blood-borne diseases, with a consequent decrease of patients’ safety 
in case of PrEP applied as a “substitute” prevention strategy. In 
addition, PrEP would generate an increase in staff workflow, with 
investment in medical supplies and training courses. PrEP would 
lead to significant economic investments both for the NHS (+40%), 
and for citizens (+2,377%) if used as an add-on strategy, assuming 
FTC/TDF patent cost. With the off-patent drug, the NHS would ben-
efit from an advantage (37%), and a shrink of the patients’ expendi-
ture emerged (+682%). More economic resources are required if 
PrEP is applied as a substitute strategy, considering both the pat-
ent (NHS: 212%; citizens: 3,423%) and the off-patent drug (NHS: 
73%; citizens: 1,077%). Conclusions. The most cost-containing 
strategy would be the use of PrEP, as an add-on strategy, with a 
consequent improvement in patients’ safety, even if drug-related 
adverse events would be considered. The implementation of the off-
patent drug would decrease the economic burden of the innovative 
prevention strategy. Hence, the organizational aspects related to its 
adoption would be deeply investigated, with the potential opportu-
nity to create specific ambulatories devoted to PrEP users’ espe-
cially for medium and big size hospitals.
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including individuals who have had sex without using 
a condom; and 5) injection drug users. In 2016, also the 
European Medicines Agency (EMA) approved the use 
of the oral TDF/FTC for PrEP in adults at high-risk for 
contracting HIV infection, and guidelines were issued 
recommending that oral PrEP should be offered as an 
additional prevention choice, for people at substantial 
risk of HIV infection, as part of combination prevention 
approaches. EDCD’s annual survey [8] revealed that by 
2019, 14 of 53  reporting countries declared that their 
national healthcare service provided reimbursed PrEP 
(Belgium, Bosnia and Herzegovina, Croatia, Denmark, 
France, Germany, Iceland, Luxembourg, Moldova, the 
Netherlands, Norway, Portugal, Sweden, and Northern 
Ireland and Scotland within the United Kingdom - UK), 
either through insurance or from the public sector. The 
results show that progress has been made since 2016, 
when only France reported that PrEP was nationally 
available and reimbursed  [9]. Despite the different 
behaviors of European Countries, the Italian provisions 
of PrEP remains limited, since, in the Italian setting, 
PrEP (as preventive strategy for high-risk people) is 
available only if totally paid by citizens.
Based on the above suggestions, while there have been a 
significant number of studies reporting the high potential 
efficacy of PrEP  [3-6], its implementation is strictly 
related to significant economic and organizational 
concerns, as well as to the different behaviours and 
adherence of high-risk populations. Besides the high 
PrEP cost, there emerged an organizational difficulty 
to guarantee an adequate hospital pathway to the HIV 
negative individuals assuming PrEP [10], since specialist 
visits, cultural blood tests and treatment of other sexually 
transmitted diseases [11], could be ensured to the PrEP 
treated population, in particular, for whom not using 
condoms or NSPs. Furthermore, the ethical aspects 
related to the medicalization of a healthy person become 
an urgent pattern, in Countries characterized by limited 
economic resources, since the use of Highly Active 
Antiretroviral Therapy (HAART) is related to several 
monitoring activities for drugs toxicities [12].
Despite the relevance of the topic, no evidence has 
emerged with regard to the potential impacts associated 
to the introduction of PrEP in the Italian clinical 
practice. Thus, the aim of the present study was a 
multi-dimensional evaluation of PrEP adoption in Italy 
(as an “add-on” or a “substitute” prevention strategy), 
compared with the traditional HIV prevention strategies, 
in order to protect high-risk HIV-negative individuals, 
useful to support evidence-based decision-making 
processes, taking into consideration the individual’s and 
the National Healthcare Service (NHS) perspectives.
Methods
An analysis was conducted involving 35 Italian 
Infectious Disease Departments in Italy, including 15 
Italian Regions, in order to achieve a complete national 
landscape of the centers devoted to the enrollment 
and treatment of these patients, in terms of regional 
distribution, centers dimensions and private/public 
ownerships.
A letter for participation to the study was sent via-mail to 
the Italian Infectious Disease clinicians, in order to gather 
information with regard to the number of potentially 
PrEP users, as well as to retrieve their perceptions with 
regard to the introduction of such preventive strategy.
Thus, the introduction of PrEP (prescribed as an “add-
on” or a “substitute” prevention strategy) into the 
clinical practice, was compared with a baseline scenario 
consisting of the use of condoms among men who have 
sex with other men (MSM), and serodiscordant couples 
(SCs), and the use of NSPs among injection drugs 
users (IDUs), thus being consistent with the guidelines 
available on the topic. The above scenarios were analyses 
by means of a Health Technology Assessment (HTA) 
approach, in order to cover all the domains required 
by the EUnetHTA Core Model according to real-life 
qualitative and quantitative information. 
Since no sensitive and human data were collected, 
both the ethics approval and the compliance with the 
STROBE guidelines for reporting observational studies, 
were not applicable.
Because of the multi-dimensional nature of HTA [13], 
the present analysis considered several aspects of the 
medical technologies under evaluation, in accordance 
with the EUnetHTA Core Model  [14]. Thus, the 
assessment of the EUnetHTA Core Model domains, was 
completed by a prioritisation phase, and a final multi-
criteria decision analysis – MCDA [15-17], simulating 
the appraisal phase.
Assessment of EUnetHTA Core Model 
domains
Due to the multi-dimensional and multi-disciplinary 
nature of HTA, several aspects of the preventive 
approaches taken into account (PrEP and other 
alternatives, in add-on or not), were analyzed as 
suggested by literature  [14]: i)  health problem and 
current use of technology; ii) description and technical 
use of technology; iii) safety; iv) clinical effectiveness; 
v)  costs and economic evaluation; vi)  ethical analysis, 
in terms of access to care; vii)  organizational aspects; 
viii) social aspects and ix) legal aspects. 
The above domains were deployed, considering 
scientific evidence, economic evaluations (quantitative 
information) and qualitative approaches (expert opinion 
and potential PrEP’s users perceptions. 
Literature review
With regard to the systematically searching medical 
literature, the PICO (Population, Intervention, 
Comparator and Outcome) was defined as follows: 
P  –  High-risk persons without HIV; I – FTC/TDF for 
pre-exposure prophylaxis; C – use of condoms among 
MSM and SCs, and use of NSPs among IDUs, to prevent 
HIV infection; O: HIV occurrence rate adverse events 
and sexually transmitted disease (STDs) incidence rate.
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Literature evidence came from the systematic search 
of literature databases (Pubmed, Embase and Cochrane 
Library). The search terms were the followings: “pre-
exposure prophylaxis”, “high-risk individuals”, “clinical 
effectiveness”, “HIV occurrence rate”, “drug-related 
adverse events”, “STDs”, “men who have sex with men - 
MSM”, “serodiscordant couples - SCs”, “injection drug 
users - IDU”. 
Peer-reviewed papers that explicitly described the 
clinical effectiveness of the different preventive strategies 
under assessment, were consequently included, and 
synthetized according to a PRISMA flow diagram, thus 
mapping out the number of records (in terms of papers) 
identified, included and/or excluded, and the reasons for 
exclusion motivated [18].
The validation of the scientific evidence available on the 
topic, was performed through the ROBINS II Cochrane 
risk of bias tool [19], and the AMSTAR-Assessing the 
Methodological Quality of Systematic Reviews check-
list, on the basis of the nature of the study included. 
Literature was used for highlighting efficacy profile in 
terms of HIV occurrence rate with or without PrEP, and 
safety profile (measured as drug-related adverse events 
rate). Since only primary evidence have been considered, 
the literature review proposed in the present paper, 
collected high-quality efficacy and safety information.
Economic evaluation
For the economic evaluation, both a process mapping 
technique [21] and a budget impact analysis [22] were 
conducted, comparing the clinical pathway costs of a 
PrEP user versus the ones related to an individual not 
using PrEP. Information was gathered according to the 
standard clinical pathway performed in the 35  Italian 
Infectious Diseases Departments involved in the study, 
by means of a Delphi approach  [23], consistent with 
International and National HIV Guidelines, and Regional 
Clinical Pathways.
The following determinants of costs were deeply 
considered: i) cost of the prevention strategies; ii) cost 
of the drug-related adverse events; iii) cost of the other 
sexually transmitted infections; and iv)  cost of the 
medical monitoring of PrEP users.
The pathways were valorized considering the 
reimbursement tariffs of the Italian NHS valid for the 
year 2018/2019 and assumed a 12-month time horizon. 
On the one hand, the cost supported by the NHS for the 
proper cure and follow-up of PrEP users, considered the 
following cost drivers, representing all the healthcare 
direct costs: specialist visits, diagnostic procedures, 
hematological exams, hospitalizations and drugs, all in 
terms of typology and quantity of healthcare services 
administered to the potential PrEP user. On the other 
hand, the cost supported by the PrEP users for the disease 
management, was calculated in terms of “out of pocket” 
healthcare expenditure, productivity loss (time spent in 
hospital valorized on the basis of the PrEP users average 
monthly gross salary), as well as the average transport 
costs (estimated according to the Italian Automotive Club 
- ACI tables price list), to reach the Infectious Disease 
Department for outpatient procedures. It should be noted 
here that on the one hand, the average monthly gross 
salary derived from the most recent JP Salary Outlook 
for Italy  [24], approaching with the Human Capital 
Method [25, 26] on the other hand, the average transport 
cost was calculated according to the average distance 
spent by the patient to reach the hospital of reference, 
that in the Italian setting is equal to 55.8 km [27].
After evaluating the management cost of the high-risk 
individuals, stratified by prevention technology, and 
including both the costs for the management of sexually 
transmitted infection and adverse events, a Budget 
Impact Analysis was developed considering a scenario 
in which PrEP is totally reimbursed by the NHS, and a 
scenario in which the drug, is directly purchased by the 
citizens (as happened in the Italian setting).
As mentioned before, all the economic analyses 
assumed both the NHS and the patient’s perspectives 
(in terms of “out-of-pocket expenditure” supported for 
the management and care of their clinical conditions), 
considering both branded and off-patent drugs costs 
(considering a 70% reduction in drug costs).
Domains investigated through qualitative 
approaches
Qualitative questionnaires were administered to 
35  clinicians referring to the 35  Infectious Diseases 
Departments involved in the study, who completed the 
questionnaire according to their own experience and 
perceptions.
The qualitative questionnaires were used for examining 
ethical, legal and organizational aspects, considering a 
comparative approach (use of PrEP as add on strategy vs 
not-use of PrEP in prevention activities), in accordance 
with a validated 7-item Likert scale ranging from 
–3 to +3  [28]. According to the above, the scenario 
consisting of the PrEP absence is always represented as 
a neutral situation, corresponding to zero value, and the 
perceptions related to the different domains, in case of 
PrEP adoption, were studied, with a comparative and 
incremental or decremental approach (the items studied 
are presented in Tab.  I) It should be noted that all the 
items used for the deployment of each qualitative domain 
derived from the EUnetHTA Core Model issues  [14], 
and were, then characterized and integrated, considering 
the specific topic of investigation.
The analysis of the social domain was conducted 
considering both the 35  clinicians and the potential 
PrEP users’ perceptions. For this last part of the sample, 
an online questionnaire, administered, using a Survey 
Monkey tool, was completed by a sexually high-
risk population, representing potential PrEP users. In 
particular, the on-line questionnaire was sent to two 
different citizens’ association, where people voluntarily 
decided to complete the questionnaire. Data were 
collected anonymously, in accordance with the EU 
Regulation n. 679 of 04.05.2016, guaranteeing privacy 
and legal issues. In addition to information with regard 
their risk factor for HIV, their PrEP knowledge, attitudes 
and willingness-to-pay were deeply investigated 
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considering a 5-item evaluation scale, ranging from a 
minimum of 1 (completely disagree) to a maximum of 5 
(completely agree).
Detailed information regarding the specific items related 
to each domain is shown in Table I.
Statistical methods
Focusing on the statistical methods, qualitative data 
were first analyzed, considering descriptive statistics. 
The existence of statistically significant differences 
(according to a significance level lower than 0.05 
p-value) was assessed in the comparison between 
i) baseline scenario and innovative scenario, with regard 
to the qualitative assessment of the domains; ii) MSM 
and heterosexuals, with regard to the online survey 
conducted with the involvement of potentially PrEP 
users in the social domain deployment. In particular, 
independents sample t-test for either parametric or not-
parametric variables were conducted.
Multi-criteria decision analysis
After the assessment of all the EUnetHTA Core Model 








Domains Description of the domains Quantitative and qualitative metrics for the evaluation Scores and their related descriptions  for the application of the MCDA 
Health 
problem and 
current use of 
the technology 
Target population eligible  
to PrEP administration  
Definition of the high-risk population, potentially eligible for PrEP,  
in accordance with the Italian epidemiological data available  
and with real-life information retrieved by the 35 Infectious Disease 
Departments involved. Thus, information with regard to the overall 
number of adult MSM, SCs and IDUs, approaching the above  
35 Departments were collected 
1 – Small number of potentially eligible PrEP 
users 
2 – Moderate number of potentially eligible 
PrEP users 







information and assessment 
of their quality 
After the definition of the PICO guiding the literature review, the paper 
included in the HTA were synthetized according to a PRISMA flow 
diagram, thus mapping out the number of records (in terms of papers) 
identified, included and/or excluded, and the reasons for exclusion 
motivated. Furthermore, the validation of the scientific evidence 
available on the topic, was performed through the ROBINS II Cochrane 
risk of bias tool, and the AMSTAR-Assessing the Methodological Quality 
of Systematic Reviews check-list , on the basis of the nature  
of the study included 
1 – Poor quality of evidence-based 
information 
2 – Medium quality  
of evidence-based information 
3 – High quality of evidence-based 
information 
Safety Rate of mild, moderate  and severe adverse events 
Identification of the possible adverse events for PrEP users, in terms  
of evidence-based incidence-rate data, with regard to drug-related 
adverse events, and sexually transmitted/blood borne infections, 
derived from literature evidence available on the topic. These events 
were also economically evaluated, in order to analyze their economic 
impact, considering both NHS and patients’ perspective, in accordance 
with the standard clinical pathways, declared by the 35 hospitals 
involved in the study – according to the Delphi methods, consistent 
with International and National HIV Guidelines, and Regional Clinical 
Pathways 
1 – The prevention strategy presents  
a significant decrease in PrEP user’s safety  
2 – The prevention strategy presents  
no impact in PrEP user’s safety 
3 – The prevention strategy presents  
a significant increase in PrEP user’s safety 
Clinical 
effectiveness Efficacy indicators 
Identification of the HIV occurrence rate related to the use of the three 
technologies (PrEP, condoms and syringes, as single prevention 
strategies or as add-on strategies), based on the evidence available,  
and validated in the Prisma Flow Chart 
1 – The prevention strategy presents  
a significant increase in HIV occurrence rate 
2 – The prevention strategy presents  
no impact in HIV occurrence rate 
3 – The prevention strategy presents  







Activity based costing 
analysis  
Clinical pathway economic evaluation, considering individual  
assuming or not assuming PrEP 
1 – The prevention strategy presents  
a substantial economic impact on the clinical 
pathway 
2 – The prevention strategy presents  
an insignificant and sustainable economic 
impact on the clinical pathway 
3 – The prevention strategy presents  
a favorable and low economic impact  
on the clinical pathway 
Budget impact analysis 
The above-mentioned clinical pathway cost per PrEP user  
was multiplied by the total number of patients potentially eligible to 
PrEP thus comparing a baseline with an innovative scenario and 
assuming different hypotheses:  
1) PrEP used as an add-on or substitute strategy;  
2) PrEP totally reimbursed by the Italian NHS or paid by the citizens;  
3) administration of the branded or the off-patent drug 
1 – The prevention strategy presents  
a substantial economic impact on both  
the NHS and individuals healthcare budget 
2 – The prevention strategy presents an 
insignificant and sustainable impact on both 
the NHS and individuals healthcare budget 
1 – The prevention strategy presents  
a favorable economic impact on both the NHS 
and individuals healthcare budget 
Ethical aspects 
 
Perceived aspects related 
to the access to care 
The 35 clinicians involved in the analysis, completed a comparative 
qualitative questionnaire, based on a 7-item Likert scale  
(ranging from-3 to +3), considering the following items:  
1) Access to care on local level; 2) Access to care for persons on a legally 
protected status; 3) Impact of the preventive strategy  
on the accessibility to care related to the management of adverse 
events; 4) Generation of healthcare migration phenomena; 5) Impact  
of the preventive strategy on the patients’ willingness to pay; 6) General 
equity; 7) Accessibility to the prevention strategy, in case of full 
payment by the potential PrEP’s users; 8) accessibility to the prevention 
strategy, in case of co-payment 
1 – The prevention strategy presents a 
decrease in the access to care for PrEP users 
at local level 
2 – The prevention strategy presents  
no impact in the access to care for PrEP users 
at local level 
3 – The prevention strategy presents an 
increase in the access to care for PrEP users 
at local level 
Social aspects 
 
Social and ethical  
perceived aspects:  
the clinicians’ point of view 
The 35 clinicians involved in the analysis, completed a comparative 
qualitative questionnaire, based on a 7-item Likert scale  
(ranging from -3 to +3), considering the following items:  
1) Ability of the drug to protect the patients’ autonomy; 2) Ability  
of the drug to protect the human rights; 3) Ability of the drug  
to protect the PrEP users’ integrity; 4) Ability of the drug to protect  
the PrEP users’ dignity; 5) Impact of the drug on the PrEP users’ 
willingness to pay; 6) Impact of the drug on PrEP users’religion;  
7) Impact of the drug on social costs; 8) Impact of the drug  
on the citizens’ medicalization; 9) Impact of the drug on the PrEP users’ 
satisfaction; 10) Impact of the drug on the PrEP users’ perceived quality 
of life; 11) Impact of the drug on the PrEP users’ lifestyle; 12) Impact  
of the drug on sexual behaviours disinhibition 
1 – The prevention strategy presents a 
decrease in individuals reported outcomes, 
considering the clinicians’ perspective 
2 – The prevention strategy presents  
no impact in individuals reported outcomes, 
considering the clinicians’ perspective 
3 – The prevention strategy presents  
an increase in individuals reported outcomes, 
considering the clinicians’ perspective 
Tab. I. Methods used for the deployment of the EUnetHTA dimensions.
continues
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approach  [17] was implemented, thus simulating the 
appraisal phase.
At first, the domains were prioritized by the 35 clinicians 
involved, using a rating scale ranging from 1 (more 
important dimension), to 9 (less important dimension).
Furthermore, the quality of the information retrieved 
for the deployment of each EUnetHTA domain was 
evaluated by three Medical Directors, that assigned to 
each sub-dimension (listed in Tab. I), a three-level mark 
(ranging from a minimum of 1 –  less performant –  to 
a maximum of 3  –  more performant  –), after having 
carefully read a first draft of the evidence proposed in 
the present manuscript, in order to fully understand 
the potential impacts of the PrEP introduction or not 
introduction. Detailed information with regard the 
specific score assigned to each domain are reported in 
Table I.
This experiment was carried out to lead to a final 
concise result, useful in the choice of the “preferable” 
technology, supporting the appraisal phase and the 
policy-making process.
The final score was obtained by multiplying the 
normalized score, calculated for each domain, with the 
normalized value of priority, as suggested by scientific 
evidence  [17]; the higher the score acquired, the more 
preferable is the technology.
Results
Assessment of the domains
Results from literature review
Out of 2,118  papers identified through databases 
searching, according to the proposed PICO of the 
study, only six of them  [3-6, 29-30] met the inclusion 
criteria, in accordance with the above-mentioned search 
strategy, focusing on the administration of PrEP for 
high-risk individuals as detailed in the Prisma Flow 
Chart for literature synthesis (Fig. 1). In particular, four 
of them [3-6] were RCTs investigating the effectiveness 
and the safety profiles within the target populations, and 
two of them [29, 30] were meta-analysis with regard to 
the effectiveness of the traditional preventive strategies. 
The rejected articles had different aims, without focusing 
the attention on efficacy/safety data, nor focusing on 
different populations than MSM, IDUs or SCs.
The literature review revealed the lack of scientific 
evidence concerning the head-to-head comparison of 
PrEP, as preventive strategy, used in add-on with the 
traditional preventive strategies (condoms or NSPs), or 
used alone, in particular observing the safety, and the 
efficacy profile of the alternatives.
Despite the above missing information, the articles 





Social and ethical perceived 
aspects: the PrEP users’ 
point of view 
Definition of the PrEP users’ awareness and knowledge with regard its 
adoption into the clinical practice, by means of an online questionnaire 
administration, filled in by potentially PrEP users 
1 – The prevention strategy presents  
a decrease in individuals reported outcomes, 
considering the potential PrEP users’ 
perspectives 
2 – The prevention strategy presents  
no impact in individuals reported outcomes, 
considering the potential PrEP users’ 
perspectives 
3 – The prevention strategy presents  
an increase in individuals reported outcomes, 
considering the potential PrEP users’ 
perspectives 
Legal aspects Legal perceived aspects 
The 35 clinicians involved in the analysis, completed a comparative 
qualitative questionnaire, based on a 7-item Likert scale  
(ranging from -3 to +3), considering the following items:  
1) Authorization level (national/European/international); 2) Legal impact 
on safety issues; 3) Infringement of intellectual property rights;  
4) Impact on the production warranties; 5) Need to regulate the drug 
acquisition and costs; 6) The legislation covers the regulation  
of technology, for all categories of users; 7) Impact on the not-
availability of PrEP in hospitals 
1 – The prevention strategy presents  
the need to regulate its acquisition  
2 – The prevention strategy presents  
no need to regulate its acquisition 
3 – The prevention strategy presents  






The 35 clinicians involved in the analysis completed a comparative 
qualitative questionnaire, using a 7-item Likert scale  
(ranging from -3 to +3), in accordance with the following aspects:  
1) Additional staff; 2) Training courses devoted to Infectious Disease 
clinicians; 3) Training courses devoted to healthcare professionals;  
4) Training courses devoted to potentially PrEP users; 5) Internal hospital 
meetings; 6) Additional rooms and services; 7) Additional furniture;  
8) Impact on the internal processes; 9) Impact on the processes  
between the Pharmaceutical Department and the Infectious Diseases 
Department; 10) Impact on the number of access; 11) Impact  
on the number of hematological exams, specialist visits related to the 
administration of the drug; 12) Impact on the management of other 
infectious diseases, different from HIV and HBV; 13) Organisational 
impact on the development of complications and adverse events;  
14) Organisational impact on the development of drug toxicities and 
resistances; 15) Impact on the taking in charge of a higher number  
of users 
1 – The prevention strategy presents  
a qualitative negative impact,  
since it requires important organizational 
efforts without any advantage  
for the hospital 
2 – The prevention strategy presents  
no qualitative organizational impact 
3 – The prevention strategy presents  
a qualitative positive impact,  
since it requires small organizational efforts 







Definition of the organizational ceasing or incremental costs related  
to the prevention strategies under assessment, considering  
additional persons, training courses, additional equipment,  
spaces or rooms 
1 – The prevention strategy requires 
important and significant organizational 
investments 
2 – The prevention strategy requires  
no or small organizational investment 
3 – The prevention strategy presents  
the possibility to free-up organizational 
resources  
 
Tab. I. Methods used for the deployment of the EUnetHTA dimensions.
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assessed, in accordance with the ROBINS II Cochrane risk 
of bias tool, the CASP checklist and the AMSTAR tool. 
Focusing on the RCTs included, useful for the retrieval of 
PrEP efficacy and safety profile, ROBINS II tool revealed 
that the risk of bias was not high.
All the studies were at low risk of bias since the 
classification of PrEP vs control was made clearly. The 
outcomes measurement proved to be relevant in most 
cases, and both positive and negative outcomes were 
determined and explained. According to scientific 
evidence [3-6], the innovative technology would lead to an 
increase in drug-related adverse events, whose incidence 
rates and economic evaluation are presented in Table II.
Furthermore, since PrEP presents a protective effect only 
with regard to HIV infection, even if used as an add-
on strategy, and considering the real-life adherence to 
condoms and NSPs strategies, individuals could acquire 
other sexually transmitted/blood borne infections  [3-
5], resulting in a final worst safety profile. The general 
population presents an HIV occurrence rate equal to 
33%  [2], with a consequent NHS resource absorption 
per patient of € 11,694.86 and an individual’s “out-of-
pocket” expenditure of € 751.94.
Focusing on the efficacy profile, the parameter used 
in the present HTA for this specific domain, was the 
ability of each strategy to prevent the individual from 
HIV infection and derived from literature evidence 
available on the topic. With regard to the baseline 
scenario, condoms and the NSPs present an efficacy rate 
equal to 99%  [29] and 17%  [30], respectively. On the 
contrary, literature declares an efficacy rate of 86% for 
MSM [3, 4], 75% for SCs [6], and 48.9% for IDUs [5], 
strictly dependent form treatment adherence [31].
Results from the economic evaluation
Before conducting the economic evaluation, the number 
of HIV negative high-risk individuals, and, thus, 
individuals potentially eligible for PrEP treatment, was 
defined. Data derived from the number of individuals 
approaching the 35  Italian Infectious Disease 
Departments involved, for the conduction of the HIV test 
or for counselling were projected. Forecasting collected 
hospital data declared, considering the entire Italian 
potential population, it emerged that at least 16,577 
individuals could be eligible for PrEP: 6,653 SCs, 5,943 
MSM and 3,981 IDUs were considered and projected in 
the present economic analysis.
At first, as reported in Table  II, the management cost 
of drug-related AEs and STDs developed by the PrEP 
population were considered.
Furthermore, the annual cost of each prevention strategy 
was accordingly investigated, assuming a 12-month time 
horizon and valorizing all the items of cost according 
to the reimbursement tariffs of the Italian NHS valid 
Fig. 1. PRISMA 2009 flow diagram.
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for the years 2018/2019. The annual average cost (per 
person) of condoms was hypothesized equal to € 192.00; 
whereas the annual average cost (per person) of NSPs 
was equal to €  75.25, being consistent with literature 
evidence [31]..On the one hand, given an average value 
for each condom equal to € 1.00, the model assumed a 
use of this strategy four times a week [6]. On the other 
hand, the average cost for a clean and sterile syringe was 
equal to € 0.056, with on average 4 doses per day [32].
With regard to the branded drug, the model assumed a 
drug cost equal to € 5,339.95 and € 9,011.28 per year 
(per person), in case of NHS reimbursement and citizens 
purchased respectively. If the off-patent drug was used 
and introduced into the clinical practice, a cost equal 
to € 1,601.99 and to € 2,703.38 was hypothesized, 
considering the NHS and the citizen’s perspective 
respectively.
In addition to the annual economic value of PrEP drug, 
its monitoring cost was evaluated. Patients should attend 
at least 2  specialist visits, and 2  follow-up medical 
controls, as well as conduct full blood test panels, 
with the inclusion of creatinine, phosphorus, urine, 
proteinuria, and tests for sexually transmitted diseases, 
such as HIV, HCV, HBV and syphilis. These procedures 
required on average € 306.40 and € 68.62 considering 
the NHS and the patient point of view respectively.
The following tables reported the budget impact analysis 
derived from the introduction of PrEP, both as an add-on, 
and as a substitute strategy to the traditional prevention 
technologies, considering branded (Tab.  III) and off-
patent (Tab. IV) drugs.
If PrEP is used as an “add-on” strategy, distributed and 
paid by the NHS, considering branded drugs, NHS 
investments would increase significantly (+40%), 
Tab. II. Safety profile.
Drug-related adverse events: incidence and costs
Drug-related 
adverse events
Men who have sex 









Nausea 8% 8% 8% € 52.74 € 22.15
Vomiting 2% 2% 5% € 52.74 € 22.15
Diarrhea 4% 4% 11% € 1,822.21 € 306.26
Abdominal pain 7% 7% 9% € 50.00 € 21.00
Bone disease 2% 2% 2% € 661.44 € 527.40
Creatinine Increase 18% 10% 7% € 1,474.61 € 549.73
Headache 8% 8% 8% € 20.07 € 8.43
Rash 8% 8% 8% € 760.13 € 264.72
Other sexually transmitted/
blood borne infections





HCV 1% 2% € 8,545.97 € 950.89
Syphilis 10% 9% € 117.75 € 49.55
Chlamydia 27% 22% € 76.00 € 31.98
Gonorrhea 38% 37% € 88.67 € 37.31
Rectal or vaginal Infection 36% 32% € 267.72 € 112.66





 100% PrEP reimbursed by the Italian NHS,  
considering branded drugs 
100% PrEP purchased by citizens,  
considering branded drugs 











Difference Difference  
% 
MSM and sexual risk € 47,049,798 € 114,119,651 € 67,069,852 143% € 47,049,798 € 20,491,208 -€ 26,558,590 -56% 
SCs € 52,670,757 € 131,873,657 € 79,202,900 150% € 52,670,757 € 29,012,864 -€ 23,657,893 -45% 
IDUs € 99,007,920 € 31,559,987 -€ 67,447,933 -68% € 99,007,920 € 24,948,467 -€ 74,059,453 -75% 
Total high-risk population € 198,728,475 € 277,553,294 € 78,824,819 40% € 198,728,475 € 74,452,539 -€ 124,275,936 -63% 











Difference Difference  
% 
MSM and sexual risk € 5,183,416 € 6,720,833 € 1,537,416 30% € 5,183,416 € 164,720,834 € 159,537,418 3078% 
SCs € 5,802,670 € 7,120,791 € 1,318,121 23% € 5,802,670 € 180,700,582 € 174,897,912 3014% 
IDUs € 6,498,759 € 2,778,990 -€ 3,719,769 -57% € 6,498,759 € 87,616,622 € 81,117,862 1248% 
Total high-risk population € 17,484,846 € 16,620,614 -€ 864,232 -5% € 17,484,846 € 433,038,038 € 415,553,192 2377% 
 100% PrEP reimbursed by the Italian NHS,  
considering off-patent drugs 
100% PrEP purchased by citizens,  
considering of patent drugs 











Difference Difference  
% 
MSM and sexual risk € 47,049,798 € 48,579,741 € 1,529,943 3% € 47,049,798 € 20,491,208 -€ 26,558,590 -56% 
SCs € 52,670,757 € 59,871,102 € 7,200,345 14% € 52,670,757 € 29,012,864 -€ 23,657,893 -45% 
IDUs € 99,007,920 € 16,772,989 -€ 82,234,931 -83% € 99,007,920 € 24,948,467 -€ 74,059,453 -75% 
Total high-risk population € 198,728,475 € 125,223,832 -€ 73,504,643 -37% € 198,728,475 € 74,452,539 -€ 124,275,936 -63% 











Difference Difference  
% 
MSM and sexual risk € 5,183,416 € 6,720,833 € 1,537,416 30% € 5,183,416 € 54,120,833 € 48,937,417 944% 
SCs € 5,802,670 € 7,120,791 € 1,318,121 23% € 5,802,670 € 59,194,728 € 53,392,058 920% 
IDUs € 6,498,759 € 2,778,990 -€ 3,719,769 -57% € 6,498,759 € 30,040,415 € 23,541,656 362% 
Total high-risk population € 17,484,846 € 16,620,614 -€ 864,232 -5% € 17,484,846 € 143,355,976 € 125,871,130 720% 
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while NHS economic benefits (-63%) are found if 
PrEP is purchased by citizens (individuals’ investment: 
+2,377%). As for off-patent drugs, the NHS would 
benefit from an advantage (-37%) and a shrinkage of the 
patients’ “out-of-pocket” expenditure (+720%).
If PrEP is introduced as a “substitute” strategy, the 
economic burden would be higher, both for the NHS 
(+212%) and the citizens’ (+3,397%). Even considering 
the off-patent drug, the NHS and patients face a relevant 
economic challenge, equal to +73% and +1,051% 
respectively.
Results from the qualitative approaches
As stated in the Method section, the qualitative 
assessment of the ethical, social and organisational 
dimensions was conducted through the involvement 
of 35 clinicians referring to different Italian Regions, 
giving a representativeness of the Italian landscape. With 
respect to the geographical origin, 49%, 31% and 20% 
of clinicians referred to north, south and islands, and 
centre of Italy respectively.
A synthesis of the clinicians’ perceptions is reported in 
Table V, in terms of incremental or decremental value of 
PrEP (from -3 to + 3), in comparison with the baseline 
scenario, without PrEP (always neural, and equal to 0).
While the use of traditional prevention strategies did not 
have an impact on the NHS accessibility, a critical impact 
on ethical aspects emerged in case of PrEP introduction 
(-0.50 vs 0.00, p  <  0.05), in particular in case of full 
payment of PrEP by the potential users (-1.84 vs 0.00, 
p < 0.05), since this drug is expensive, thus limiting its 
accessibility to the different population categories.
However, the clinicians declared an improvement both 
in the PrEP users’ quality of life (0.58 vs 0.00, p < 0.05) 
and in their satisfaction (1.52 vs 0.00, p < 0.05), even 
if professionals have the perception of disinhibition of 
the sexual behavior of the individuals who assume PrEP 
(-2.20 vs 0.00, p  <  0.05), thus being consistent with 
literature evidence [33-37].
From a legal point of view, investments are required 
to regulate the use of PrEP in hospitals (-1.21 vs 0.00, 
p  <  0.05). Despite the EMA approval, in Italy the 
administration of this preventive strategy should be 
regulated and inserted in the clinical protocols.
With regard to the organizational impact, clinicians 
declared an increase in staff workflow (-1.62 vs 0.00, 
p < 0.05) due to the high number of HIV negative patients 
attending regular doctor appointments, and follow-up 
procedures, thus requiring additional clinicians (-1.44 
vs 0.00, p  <  0.05). The assessment of the quantitative 
organizational impact, assuming a 12-month time 
horizon, confirmed their perceptions, considering an 
Infectious Disease Department (taking in charge on 
average 745 HIV+ treatment-experienced and 32 HIV+ 
treatment-naïve individuals, 777 in total). There emerged 
the need to invest in additional working professionals, 
as well as to organize specific training courses devoted 
to individuals directly involved in the provision of 
PrEP to the citizens. At least 2  clinicians, 2  nurses, 
and 1  psychologist could be involved in the training 
activities, with an economic resources’ absorption equal 
to € 1,750.00 only for the first year.
Ninety percent of the Infectious Disease Department 
involved in the analysis, required the creation of a 
new ambulatory devoted to the high-risk population 
potentially assuming PrEP, with a consequent additional 
investment in both medical supplies and equipment, for 
an average amount equal to € 666.26 and to € 1,158.7 
respectively. At the 12-month time point of the base-case 
scenario for market penetration, a medium size hospital 
would invest on average a total amount of € 3,574.96, for 
organizational arrangements.





 100% PrEP reimbursed by the Italian NHS,  
considering branded drugs 
100% PrEP purchased by citizens,  
considering branded drugs 











Difference Difference  
% 
MSM and sexual risk € 44,524,325 € 126,062,875 € 81,538,550 183% € 44,524,325 € 35,401,844 -€ 9,122,482 -20% 
SCs € 31,786,125 € 150,349,598 € 118,563,473 373% € 31,786,125 € 52,557,382 € 20,771,257 65% 
IDUs € 45,636,657 € 104,088,731 € 58,452,074 128% € 45,636,657 € 50,601,093 € 4,964,435 11% 
Total high-risk population € 121,947,108 € 380,501,204 € 258,554,096 212% € 121,947,108 € 138,560,318 € 16,613,210 14% 











Difference Difference  
% 
MSM and sexual risk € 5,360,454 € 6,149,260 € 788,806 15% € 5,360,454 € 159,141,693 € 153,781,239 2869% 
SCs € 3,826,853 € 6,895,607 € 3,068,754 80% € 3,826,853 € 171,922,065 € 168,095,212 4393% 
IDUs € 2,995,535 € 4,658,200 € 1,662,665 56% € 2,995,535 € 94,919,735 € 91,924,200 3069% 
Total high-risk population € 12,182,842 € 17,703,066 € 5,520,224 45% € 12,182,842 € 425,983,493 € 413,800,651 3397% 
 100% PrEP reimbursed by the Italian NHS,  
considering off-patent drugs 
100% PrEP purchased by citizens,  
considering off-patent drugs 











Difference Difference  
% 
MSM and sexual risk € 44,524,325 € 62,600,238 € 18,075,913 41% € 44,524,325 € 35,401,844 -€ 9,122,482 -20% 
SCs € 31,786,125 € 81,895,138 € 50,109,013 158% € 31,786,125 € 52,557,382 € 20,771,257 65% 
IDUs € 45,636,657 € 66,647,434 € 21,010,777 46% € 45,636,657 € 50,601,093 € 4,964,435 11% 
Total high-risk population € 121,947,108 € 211,142,810 € 89,195,703 73% € 121,947,108 € 138,560,318 € 16,613,210 14% 











Difference Difference  
% 
MSM and sexual risk € 5,360,454 € 6,149,260 € 788,806 15% € 5,360,454 € 52,046,922 € 46,686,468 871% 
SCs € 3,826,853 € 6,895,607 € 3,068,754 80% € 3,826,853 € 56,403,471 € 52,576,618 1374% 
IDUs € 2,995,535 € 4,658,200 € 1,662,665 56% € 2,995,535 € 31,736,620 € 28,741,086 959% 
Total high-risk population € 12,182,842 € 17,703,066 € 5,520,224 45% € 12,182,842 € 140,187,013 € 128,004,171 1051% 
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Focusing on the potentially PrEP users’ perceptions, 
the on-line survey involved 129 individuals referring 
to two different citizens’ associations. Individuals were 
well-matched in terms of homosexuals (MSM) and 
heterosexuals (54% vs 46%) risks factors. The sample 
presented scarce knowledge of PrEP (2.78 ± 1.19), even 
if MSM reported a better awareness in comparison with 
heterosexuals (2.99 vs 2.54, p = 0.035). Individuals also 
declared poor information sharing, both from healthcare 
agencies and medical providers (1.77±0.72), and from 
Tab. V. Clinicians’ perceptions.
The clinicians’ perceptions
Ethical aspects PREP No PREP
Access to care on local level 0.25 0.00
Access to care for persons on a legally protected status 0.69 0.00
Impact of the preventive strategy on the accessibility to care related to the management of adverse events -0.81 0.00
Generation of health migration phenomena 0.43 0.00
Impact of the preventive strategy on the patients’ willingness to pay -1.19 0.00
General equity -0.44 0.00
Accessibility to the prevention strategy, in case of full payment by the potential PrEP users -1.84 0.00
Accessibility to the prevention strategy, in case of co-payment. -1.09 0.00
Average value -0.50 0.00
Social aspects PREP No PREP
Ability of the drug to protect the potential PrEP users’ autonomy 0.00 0.00
Ability of the drug to protect the human rights 0.00 0.00
Ability of the drug to protect the potential PrEP users’ integrity 0.00 0.00
Ability of the drug to protect the potential PrEP users’ dignity 0.00 0.00
Impact of the drug on potential PrEP users’ religion 0.00 0.00
Impact of the drug on social costs -1.76 0.00
Impact of the drug on the citizens’ medicalization -0.91 0.00
Impact of the drug on the potential PrEP users’ satisfaction 1.52 0.00
Impact of the drug on the potential PrEP users’ perceived quality of life 0.98 0.00
Impact of the drug on the potential PrEP users’ lifestyle 0.19 0.00
Impact of the drug on sexual behaviors disinhibition -2.21 0.00
Average value -0.20 0.00
Legal aspects PREP No PREP
Authorization level (national/European/international) -1.94 0.00
Legal impact on safety issues -1.18 0.00
Infringement of intellectual property rights -0.48 0.00
Impact on the production warranties -0.79 0.00
Need to regulate the drug acquisition and costs -1.48 0.00
The legislation covers the regulation of technology for all categories of patients -1.00 0.00
Impact on the not-availability of PrEP in hospitals -1.58 0.00
Average value -1.21 0.00
Organisational aspects PREP No PREP
Additional staff -1.44 0.00
Training courses devoted to Infectious Disease clinicians -1.35 0.00
Training courses devoted to healthcare professionals -1.41 0.00
Training course devoted to potentially PrEP users -1.38 0.00
Internal hospital meetings -1.35 0.00
Additional rooms -1.00 0.00
Additional furniture -0.59 0.00
Impact on the internal processes -1.26 0.00
Impact on the processes between the Pharmaceutical Department and the Infectious Diseases Department -0.76 0.00
Impact of the number of access for conducting HIV tests -0.68 0.00
Impact on the number of hematological exams, specialist visits related to the administration of the drug -1.68 0.00
Impact on the management of other infectious diseases, different from HIV and HBV -2.06 0.00
Organisational impact on the development of complications and adverse events -0.47 0.00
Organisational impact on the development of drug toxicities and resistance -1.21 0.00
Impact on the taking in charge of a higher number of individuals -1.62 0.00
Average value -1.22 0.00
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media information (1.51 ± 0.06). In this view, statistically 
significant differences emerged between MSM and 
heterosexuals, with regard to the perception concerning 
the quality of information from healthcare agencies and 
medical providers (1.60 vs 1.97, p = 0.010).
A total of 69 individuals (only 53.48% of the entire sample), 
revealed their intention to pay for the administration 
of PrEP, by introducing the drug into their personal 
healthcare budget, showing no difference between MSM 
and heterosexuals (50.7% vs 49.3%, p>0.05). Despite 
70% (n = 49) of the individuals having the intention to 
pay for PrEP had a job, no relations emerged between 
the job category and the willingness to pay for PrEP 
(p > 0.05), thus leading to the fact that having a job is not 
a determinant of the individuals’ willingness-to-pay.
The sample agreed that PrEP is not responsible of 
any modification of daily activities (1.82  ±  0.20), 
sexual behaviors (2.33  ±  0.11), as well as a possible 
accentuation of sexual disinhibition (2.18  ±  0.10), 
with no statistically significant differences between 
the two groups. In addition, they do not think that the 
development of drug-related adverse events could 
be a reason for PrEP discontinuation (2.78  ±  0.09), 
adhering to their treatment, in order to achieve clinical 
effectiveness. However, they felt slightly uncomfortable 
in going to the hospital to obtain PrEP (3.09  ±  0.09), 
and in conducting diagnostic and blood tests for PrEP 
(3.29 ± 0.09), as follow-up procedures.
Appraisal phase
The experimental appraisal phase required both a 
prioritisation of the domains (performed by the 35 Infectious 
Disease Clinicians), and the implementation of a multi-
criteria decision approach (based on the above results 
and the marks proposed by three Medical Directors). The 
prioritization reported that the most important aspects 
were both safety and efficacy profiles, as well as the 
social domain. The MCDA revealed that the adoption 
of PrEP resulted in a score of 0.484, underlying a 
disadvantage for acquiring the new HIV prevention 
strategy, with respect to the baseline scenario (0.516), 
even if the alternative technology could present a positive 
impact from a safety and social perspective (Tab. VI).
Discussion
PrEP is now established as a biomedical HIV prevention 
approach, with the potential to contribute significantly 
to global HIV prevention efforts and decreased HIV 
incidence rates, in several different populations 
considered at high-risk of acquiring HIV.
However, the population health benefits and costs of 
adopting PrEP remain unclear, since there are multiple 
barriers to worldwide provision of PreP to all eligible 
high-risk populations [38]. Concerns around safety and 
potential side effects, effectiveness, cost, and adherence 
challenges become key issues to be considered. Thus, 
the present study paved the way to the determination of 
potential strengths and weaknesses of PrEP adoption 
into the clinical practice.
Accordingly, advantages include a reduction of HIV 
infection, if associated with the traditional prevention 
strategies (only if PrEP is used as an “add-on” strategy), 
as demonstrated in recent clinical trials with regard to 
the administration of PrEP to IDUs [5], MSM [3,4] and 
SCs  [6]. This consideration would suggest that PrEP 
could substantially reduce the lifetime risk of HIV 
infection for individuals at high-risk also in Italy, thus 
protecting the community from HIV infection.
Results showed that PrEP would increase satisfaction 
and quality of life for its users, justifying the social 
acceptance and implications of the drug. Focusing 
the attention on the potential population eligible to 
PrEP, the study reported a limited knowledge of PrEP 
in Italy, suggesting the setting up and implementation 
of PrEP training programs, targeted at the eligible 
population through public health campaigns, in order 
to raise awareness and disseminate correct information. 
In this regard, efforts should be taken to challenge the 
stigma and marginalization of minority groups, such 
as IDUs and MSM, both within the community and at 
governmental level.
However, PrEP would also provoke safety and economic 
concerns that should be taken into consideration from 
the policy-makers point of view, and that significantly 
impact both on Italian healthcare expenditure and on 
the citizens’ healthcare budget. The deployment of 
Tab. VI.  Appraisal phase.












Health problem and current use 
of technology
0.471 0.529 0.044 0.021 0.024
Description and technical 
characteristics
0.500 0.500 0.022 0.011 0.011
Safety 0.438 0.563 0.178 0.078 0.100
Clinical effectiveness 0.545 0.455 0.200 0.109 0.091
Cost and economic evaluation 0.611 0.389 0.133 0.081 0.052
Ethical analysis 0.625 0.375 0.089 0.056 0.033
Social aspects 0.485 0.515 0.156 0.075 0.080
Legal aspects 0.375 0.625 0.067 0.025 0.042
Organisational aspects 0.538 0.462 0.111 0.060 0.051
Total 4.588 4.412   0.516 0.484
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the safety profile, derived from the HTA exercise, is 
consistent with scientific evidence available. Despite 
PrEP remaining significantly protective against HIV 
infection, its general safety is strictly related to the high-
risk population behaviors, in terms of development of 
other sexually transmitted diseases if used as a substitute 
prevention strategy. In addition, some studies reported 
small, subclinical decreases in liver function [6, 39] and 
bone mineral density [40, 41].
Focusing on the economic impact, results revealed the 
impossibility for the Italian NHS to cover the cost of 
drugs, despite nowadays the off-patent drug is available. 
In particular, the acquisition of PrEP especially depends 
on its reimbursement and consumption, with the 
generation of financial problems, both in term of NHS 
investment and in terms of citizens’ “out-of pocket” 
expenditure.
However, except for the cost of the preventive strategy 
itself, the management of the potential PrEP users’, 
thus considering also the so-called risk compensation, 
require additional healthcare investments, since the need 
to intensively monitor the PrEP users, with a consequent 
negative organizational impact, due to the taking in 
charge of more patients. 
At least, in the investigated setting, the best cost-
containing strategy would be the use of PrEP with off-
patent molecules, thus decreasing the economic burden 
of the innovative prevention strategy. Hence, in order to 
limit the need of the above-mentioned organizational 
investment, the potential opportunity to create specific 
ambulatories devoted to PrEP users’ especially for 
medium and big size hospitals should be considered. 
Moving on from these elements, and considering the 
results derived from the MCDA approach, the decision 
to not implement PrEP into the clinical practice, with 
a public expenditure, could be the preferable option, 
at least, within the Italian healthcare setting. However, 
the quantitative difference between the baseline and the 
innovative scenario is not significant (0.516 vs 0.484, 
p > 0.05), thus leading to the consideration that the use 
of PrEP could be a positive solution devoted to high-risk 
patients given its high clinical effectiveness if applied 
as an “add-on” strategy considering the off-patent drug 
cost. The social, economic and organizational conditions 
of the Italian NHS could not be ready yet for the 
introduction of the prophylaxis, requiring the definition 
of proper clinical pathways to become sustainable. 
Given this fact, the preferable solution could be the 
adoption of PrEP as an “add-on” prevention strategy, 
but supposing also a co-payment, in order to guarantee 
the sustainability and affordability of the strategy. 
Considering a 50% co-payment, with the branded drugs, 
an economic burden emerged both for the NHS (+26%) 
and the patients (1,193%), whereas, with the off-
patent drug the NHS would benefit from an economic 
advantage equal to -53% and patients would invest for 
218%, in comparison with a baseline scenario consisted 
of the purchase of condoms and NSPs.
A future step of further research could be the integration 
of the present results, considering the innovative 
molecules emtricitabine/tenofovir alafenamide (FTC/
TAF), that has been recently approved for PrEP use, by 
the American Food and Drugs Administration (FDA). 
The introduction of TAF, instead of TDF, could thus 
improve the economic resources absorption of the 
innovative preventive strategy, but also the safety profile, 
in terms of management cost for drug-related side effect. 
TAF regimen has a reduced potential for causing kidney 
injury and thinning bones than TDF, with a consequent 
positive impact both on the economic pathway, and 
on the organisational aspects, with a lower impact of 
controls, laboratory exams and specialistic visits.
In conclusions, since the study was not design for the 
collection of PrEP users’ reported outcome, in terms 
of quality of life, it could be interesting to investigate 
this topic thus examining the head to head differences 
between PrEP users and high-risk individuals, not 
assuming PrEP.
Conclusions
To the best of the authors’ knowledge, this study could 
be considered the first attempt to fully evaluate the 
implications derived from the PrEP introduction into 
the clinical practice, with an holistic vision of all the 
impacts that could play an important role in the PrEP 
introduction’ choice, offering new insights to advance the 
ongoing debate regarding the relevance and feasibility of 
its adoption, in contexts characterized by the paucity of 
economic and human resources.
On the whole, a proper stratification of the potential 
population eligible to PrEP could optimize the clinicians’ 
choice and the correct use of PrEP, with a lower and 
more sustainable economic impact, and a maximization 
of both safety and efficacy profile. In particular, the 
individuals who are at risk, should identify themselves to 
their doctors, and every effort should be made, to ensure 
that a safe, stigma-free environment is created for them.
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